# Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

> **NCT00239863** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 684 (—)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** FTY720

## Key facts

- **NCT ID:** NCT00239863
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 684 (—)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239863, "Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00239863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*